Gabapentin for once-daily treatment of post-herpetic neuralgia: a review

Benjamin Beal,1 Tobias Moeller-Bertram,1,2 Jan M Schilling,1 Mark S Wallace11Division of Pain Medicine, Department of Anesthesiology, University of California, 2VA San Diego Healthcare System, San Diego, CA, USAAbstract: Post-herpetic neuralgia is a neuropathic pain syndrome resulting from an insult...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beal B, Moeller-Bertram T, Schilling JM, Wallace MS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Gabapentin Gabapentin extended release Post Herpetic Neuralgia Neuropathic Pain Aging Population Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/637aa5d565714f39967e1a2c101497d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:637aa5d565714f39967e1a2c101497d1
record_format	dspace
spelling	oai:doaj.org-article:637aa5d565714f39967e1a2c101497d12021-12-02T02:44:18ZGabapentin for once-daily treatment of post-herpetic neuralgia: a review1178-1998https://doaj.org/article/637aa5d565714f39967e1a2c101497d12012-07-01T00:00:00Zhttps://www.dovepress.com/gabapentin-for-once-daily-treatment-of-post-herpetic-neuralgia-a-revie-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Benjamin Beal,1 Tobias Moeller-Bertram,1,2 Jan M Schilling,1 Mark S Wallace11Division of Pain Medicine, Department of Anesthesiology, University of California, 2VA San Diego Healthcare System, San Diego, CA, USAAbstract: Post-herpetic neuralgia is a neuropathic pain syndrome resulting from an insult to the peripheral and central nervous systems caused by the varicella zoster virus. Spontaneous pain may result in the persistent sensation of burning, tingling, or aching and may be associated with thermally or mechanically provoked pain, resulting in hyperalgesia or allodynia. The majority of cases occur in patients over the age of 50 years. Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α2-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release. Gabapentin is effective in reducing neuropathic pain due to post-herpetic neuralgia when given at least three times per day, due to its short half-life, resulting in demonstrable fluctuations in plasma levels. Gabapentin has dose-limiting side effects that prevent some patients from achieving therapeutic plasma levels, such as somnolence (27.4%), dizziness (23.9%), and ataxia (7.1%). Gralise™ is a once-daily extended-release formulation of gabapentin that has been developed using AcuForm™ technology. AcuForm is a polymer-based drug delivery system that retains the tablet in the stomach and upper gastrointestinal tract for a sustained period of time. Once-daily dosing has been shown to provide comparable drug exposure with an identical daily dose of the immediate-release formulation when administered three times daily. Participants given Gralise 1800 mg daily had a statistically significant reduction in average daily pain intensity scores compared with placebo, reduced sleep interference due to pain, and a greater percent of participants reporting being much or very much improved on the patient global impression of change. An analysis comparing the efficacy and safety profiles in the aging population (≥65 years) with those younger than 65 years showed that Gralise is effective and well tolerated in both age groups.Keywords: gabapentin, gabapentin extended-release, post-herpetic neuralgia, neuropathic pain, aging populationBeal BMoeller-Bertram TSchilling JMWallace MSDove Medical PressarticleGabapentinGabapentin extended releasePost Herpetic NeuralgiaNeuropathic PainAging PopulationGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 249-255 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Gabapentin Gabapentin extended release Post Herpetic Neuralgia Neuropathic Pain Aging Population Geriatrics RC952-954.6
spellingShingle	Gabapentin Gabapentin extended release Post Herpetic Neuralgia Neuropathic Pain Aging Population Geriatrics RC952-954.6 Beal B Moeller-Bertram T Schilling JM Wallace MS Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
description	Benjamin Beal,1 Tobias Moeller-Bertram,1,2 Jan M Schilling,1 Mark S Wallace11Division of Pain Medicine, Department of Anesthesiology, University of California, 2VA San Diego Healthcare System, San Diego, CA, USAAbstract: Post-herpetic neuralgia is a neuropathic pain syndrome resulting from an insult to the peripheral and central nervous systems caused by the varicella zoster virus. Spontaneous pain may result in the persistent sensation of burning, tingling, or aching and may be associated with thermally or mechanically provoked pain, resulting in hyperalgesia or allodynia. The majority of cases occur in patients over the age of 50 years. Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α2-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release. Gabapentin is effective in reducing neuropathic pain due to post-herpetic neuralgia when given at least three times per day, due to its short half-life, resulting in demonstrable fluctuations in plasma levels. Gabapentin has dose-limiting side effects that prevent some patients from achieving therapeutic plasma levels, such as somnolence (27.4%), dizziness (23.9%), and ataxia (7.1%). Gralise™ is a once-daily extended-release formulation of gabapentin that has been developed using AcuForm™ technology. AcuForm is a polymer-based drug delivery system that retains the tablet in the stomach and upper gastrointestinal tract for a sustained period of time. Once-daily dosing has been shown to provide comparable drug exposure with an identical daily dose of the immediate-release formulation when administered three times daily. Participants given Gralise 1800 mg daily had a statistically significant reduction in average daily pain intensity scores compared with placebo, reduced sleep interference due to pain, and a greater percent of participants reporting being much or very much improved on the patient global impression of change. An analysis comparing the efficacy and safety profiles in the aging population (≥65 years) with those younger than 65 years showed that Gralise is effective and well tolerated in both age groups.Keywords: gabapentin, gabapentin extended-release, post-herpetic neuralgia, neuropathic pain, aging population
format	article
author	Beal B Moeller-Bertram T Schilling JM Wallace MS
author_facet	Beal B Moeller-Bertram T Schilling JM Wallace MS
author_sort	Beal B
title	Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
title_short	Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
title_full	Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
title_fullStr	Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
title_full_unstemmed	Gabapentin for once-daily treatment of post-herpetic neuralgia: a review
title_sort	gabapentin for once-daily treatment of post-herpetic neuralgia: a review
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/637aa5d565714f39967e1a2c101497d1
work_keys_str_mv	AT bealb gabapentinforoncedailytreatmentofpostherpeticneuralgiaareview AT moellerbertramt gabapentinforoncedailytreatmentofpostherpeticneuralgiaareview AT schillingjm gabapentinforoncedailytreatmentofpostherpeticneuralgiaareview AT wallacems gabapentinforoncedailytreatmentofpostherpeticneuralgiaareview
_version_	1718402164587495424

Gabapentin for once-daily treatment of post-herpetic neuralgia: a review

Ejemplares similares